HIGHLIGHTS
- who: Lorcan McGarvey from the Albert Einstein College of Medicine, Montefiore Medical Center, Division of Critical Care Medicine, Bronx, NY, USA have published the paper: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough, in the Journal: (JOURNAL)
- what: The aim of this phase 2b study was to determine the optimal dose of sivopixant to treat adults with RCC/UCC. The P value was generated based on the model described above; P and amp;lt; 0.05 was considered statistically significant. Placebo . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.